
PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer
Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung c
Audio Journal of Oncology
September 9, 2022

By Peter M Goodwin
PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO).
Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute, Consultant Oncologist at University College London Hospital specializing in Thoracic Oncology and ESMO Scientific Co-Chair, told the Audio Journal of Oncology that prevention was better than cure wherever possible, and that the oncogenic mechanisms his group’s research had uncovered held important keys to reducing the cancer burden globally.
Swanton’s group had investigated the relationship between air pollution and lung cancer in never smokers. “We’ve tried to establish how air pollution causes lung cancer,” he told OT. “Through a series of steps involving animal models and human analyses we’ve found that air pollution results in the release of a cytokine called: interleukin 1-beta from epithelial cells in the lung, that generates and transforms cells with pre-existing mutations—that occur normally due to aging—into tumor cells.”
He discussed his findings during the ESMO congress in Paris with the Audio Journal of Oncology’s Peter Goodwin.
More from ESMO 2022
All 4 interviewsThis is the last of the 4 ESMO 2022 interviews. See them all.
Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies
MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.